Madopar

Levodopa and benserazide hydrochloride, the active ingredients in Madopar, are a dopamine precursor with dopa decarboxylase inhibitor presented as tablets for oral use. They are indicated for the management of Parkinson's disease and Parkinsonian syndromes in adult patients, improving motor function by restoring central dopamine levels.

GNH USA supplies Madopar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards. The company ensures product quality through rigorous testing and secure logistics.

Madopar, a dopamine precursor combined with a decarboxylase inhibitor, is used in the treatment of Parkinsonian disorders. - Parkinson's disease: improves motor symptoms such as bradykinesia, rigidity and tremor. - Parkinsonian syndrome: alleviates motor deficits associated with secondary Parkinsonism. - Levodopa‑responsive Parkinsonism: provides symptomatic relief when symptoms respond to levodopa therapy.

Madopar may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: gastrointestinal discomfort, especially early in therapy. - Vomiting: expulsion of stomach contents, may accompany nausea. - Dizziness: sensation of light‑headedness or imbalance. - Orthostatic hypotension: drop in blood pressure upon standing causing faintness. - Dry mouth: reduced salivation leading to oral discomfort. - Somnolence: increased sleepiness or fatigue during the day.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare life‑threatening reaction with fever, muscle rigidity and autonomic instability. - Severe dyskinesia: uncontrolled involuntary movements that can impair function. - Psychosis: hallucinations or delusional thinking, particularly in older patients. - Cardiac arrhythmia: abnormal heart rhythm that may be life‑threatening.

When prescribing Madopar, several precautions should be considered to minimize risks and ensure safe use. - Renal impairment: adjust dose or monitor closely in patients with reduced kidney function. - Hepatic impairment: use caution in liver disease as metabolism may be affected. - Cardiovascular disease: monitor blood pressure and heart rate due to risk of orthostatic hypotension. - Psychiatric history: patients with prior psychosis may experience hallucinations. - Concomitant MAO‑B inhibitors: avoid co‑administration to reduce hypertensive crisis risk. - Store at ambient temperature: keep tablets below 25 °C in original packaging, protect from moisture and light.

Madopar can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: may cause hypertensive crisis when combined with levodopa. - Antipsychotics (e.g., haloperidol): can antagonize dopamine effects, reducing therapeutic benefit. - High‑dose pyridoxine (vitamin B6): increases peripheral levodopa metabolism, decreasing central availability.

Moderate Interactions (Monitor Closely): - Iron supplements or antacids: may reduce levodopa absorption; separate dosing by at least 2 hours. - Selective MAO‑B inhibitors (e.g., selegiline): increase levodopa levels, requiring dose adjustment. - Carbidopa: similar dopa decarboxylase inhibition; may enhance effect but also side‑effects.